Loading...
01/10 23:29
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call shows strong financial performance, with a significant turnaround in net income and improved margins. The Q&A section highlights growth in new customer acquisition and potential market expansion, although some uncertainties remain regarding study results and supply chain issues. Overall, the financial health and growth prospects suggest a positive outlook for the stock price.
Total Net Sales (Q4 2024) $29.1 million, a 37% increase year-over-year.
Net Income (Q4 2024) $7.2 million, a substantial increase from $0.1 million in Q4 2023.
Total Net Sales (Full Year 2024) $99.6 million, a 19% growth year-over-year.
Net Income (Full Year 2024) $8.6 million, a turnaround from a net loss of $4.9 million in 2023.
Cash Flow from Operations (Full Year 2024) $12.1 million, up from $7.1 million in the prior year.
Gross Margins (Q4 2024) 62.5%, improved by 150 basis points from 61% in Q4 2023.
Selling and Marketing Expenses (Q4 2024) 29.9% of net sales, improved by 90 basis points from 30.8% in Q4 2023.
General and Administrative Expenses (Full Year 2024) Decreased by $4.4 million year-over-year.
Operating Income (Q4 2024) $7.1 million, compared to an operating loss of $200,000 in Q4 2023.
Cash Balance (End of 2024) $44.7 million with no debt.
Niagen Plus product line: Launched Niagen Plus product line and introduced Niagen IV and injections at clinics through a compound pharmacy network.
Niagen IV availability: Niagen IV is now available in about 500 clinics nationwide.
E-commerce growth: E-commerce channel experienced robust organic growth with net sales of $17.3 million, a 30% increase year-over-year.
Pharmaceutical-grade Niagen sales: Pharmaceutical-grade Niagen ingredient business had net sales of $5.3 million, a 96% increase year-over-year.
Gross margins: Gross margins improved by 150 basis points to 62.5% compared to 61% in the fourth quarter of 2023.
Selling and marketing expenses: Selling and marketing expenses as a percentage of net sales improved 90 basis points to 29.9% compared to 30.8% in the fourth quarter of 2023.
Company name change: Announcement of a company name change to better represent the evolution and strategic direction of the company.
FDA communication: Initiated communication with the FDA for an investigational new drug application for NR in the treatment of ataxia telangiectasia.
Competitive Pressures: The company faces increasing competition as more companies enter the NAD-boosting market, some of which engage in misleading practices, patent infringements, and false claims.
Regulatory Issues: ChromaDex is actively communicating with the FDA regarding an investigational new drug application, indicating potential regulatory challenges in the approval process.
Supply Chain Challenges: The launch of the Niagen Plus product line faced delays of 2 to 3 months due to supply chain issues, although these have since been resolved.
Economic Factors: Global market conditions and economic factors could impact the company's operations and financial results, as noted in the forward-looking statements.
R&D Investment Risks: Increased R&D expenses are anticipated, which may affect profitability if not managed effectively.
General and Administrative Expenses: An expected increase in general and administrative expenses by $5 million to $6 million could impact financial performance.
Niagen Product Expansion: ChromaDex plans to expand the sale of Niagen products and ingredients in new markets, including the launch of Niagen Plus and Niagen IV in clinics.
FDA Communication: The company is pursuing an investigational new drug application for the use of NR in the treatment of ataxia telangiectasia and is working with the FDA on feedback.
Company Name Change: ChromaDex will announce a name change to better represent the evolution and strategic direction of the company.
2025 Net Sales Growth: ChromaDex projects approximately 18% growth in net sales for 2025, reflecting continued expansion in e-commerce and established partnerships.
Gross Margin Improvement: A modest improvement in gross margins is anticipated due to supply chain optimizations and cost-saving initiatives.
R&D Expenses: R&D expenses are expected to increase year-over-year in absolute dollars, remaining stable at 6% of net sales.
General and Administrative Expenses: General and administrative expenses are expected to increase by approximately $5 million to $6 million due to investments in business growth.
Share Repurchase Program: None
The earnings call shows strong financial performance, with significant revenue growth and improved net income. The strategic partnership and strong balance sheet are positive indicators. Despite some uncertainties in the Q&A, such as the new partnership's feedback and rollout timelines, the overall sentiment is positive due to the optimistic outlook on margins and potential market expansion. The absence of debt and increased cash flow bolster the positive sentiment. Without market cap data, a precise prediction is challenging, but overall indicators suggest a positive impact on the stock price.
The earnings call presented robust financial performance with a 38% revenue increase and a $5.1 million net income. The company has a strong cash position with no debt and has initiated a $10 million share buyback program. Despite some regulatory uncertainties, the strong growth in e-commerce and ingredient business, coupled with strategic market expansion plans, and positive product reception indicate a strong positive sentiment. The lack of market cap data suggests potential for a strong stock price reaction.
The earnings call reveals strong financial performance with a 38% YoY revenue increase, improved gross margins, and a significant net income turnaround. The company also raised its revenue growth outlook to 20%-25%. Despite competitive pressures, the launch of NIAGEN IV and plans for market expansion are promising. The Q&A section highlighted strong interest in new products, although some promotional strategies remain unclear. The lack of debt and strong cash position further enhance financial stability. Overall, the positive financial metrics and optimistic guidance outweigh the concerns, suggesting a positive stock price reaction.
The earnings call shows strong financial performance, with a significant turnaround in net income and improved margins. The Q&A section highlights growth in new customer acquisition and potential market expansion, although some uncertainties remain regarding study results and supply chain issues. Overall, the financial health and growth prospects suggest a positive outlook for the stock price.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
